MLX 7005
Alternative Names: MLX-7005Latest Information Update: 07 Feb 2025
At a glance
- Originator Biolexis Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 21 Jun 2024 Preclinical trials in Obesity in USA (PO), prior to June 2024
- 21 Jun 2024 Preclinical trials in Type 2 diabetes mellitus in USA (PO), prior to June 2024
- 21 Jun 2024 Pharmacodynamics data from preclinical studies in Obesity and Type 2 diabetes presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)